These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Alternative methods of cladribine administration. Lauria F; Cencini E; Forconi F Leuk Lymphoma; 2011 Jun; 52 Suppl 2():34-7. PubMed ID: 21504286 [TBL] [Abstract][Full Text] [Related]
8. [Subcutaneous therapy of hairy cell leukemia with 2-chlorodeoxyadenosine]. Nielsen OJ; Hippe E; Priø TK; Juliusson G Ugeskr Laeger; 1994 Apr; 156(16):2407-9. PubMed ID: 7912015 [TBL] [Abstract][Full Text] [Related]
9. [Hairy cell leukemia treated with cladribine]. Ghanima W; Heldal D; Tjønnfjord GE Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1094-7. PubMed ID: 12043051 [TBL] [Abstract][Full Text] [Related]
10. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia. Yang MH; Ho CH Zhonghua Yi Xue Za Zhi (Taipei); 2001 Jan; 64(1):54-8. PubMed ID: 11310372 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of one hairy cell leukemia case with single course of cladribine]. Zhang LJ; Qiu HX; Li JY Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):336. PubMed ID: 21729604 [No Abstract] [Full Text] [Related]
12. Ocular manifestation of hairy cell leukemia with dramatic response to 2-chloro-deoxy-adenosine. Robinson A; Eting E; Zeidman A; Djaldetti M; Mittelman M; Savir H Am J Ophthalmol; 1996 Jan; 121(1):97-9. PubMed ID: 8554090 [TBL] [Abstract][Full Text] [Related]
13. Phase II clinical study of cladribine in the treatment of hairy cell leukemia. Machii T; Chou T; Suzuki M; Ohe Y; Katagiri S; Kitano EK; Kitano K; Fujiyama Y; Izumi T; Shimazaki C; Nanba K; Ohashi Y; Kitani T; Int J Hematol; 2005 Oct; 82(3):230-5. PubMed ID: 16207596 [TBL] [Abstract][Full Text] [Related]
14. Weekly intermittent 2-CdA is less toxic and equally efficacious when compared to continuous infusion in hairy cell leukaemia. Chacko J; Murphy C; Duggan C; O'Briain DS; Browne PV; McCann SR Br J Haematol; 1999 Jun; 105(4):1145-6. PubMed ID: 10554836 [No Abstract] [Full Text] [Related]
16. Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia. Forconi F; Toraldo F; Sozzi E; Amato T; Raspadori D; Lauria F Leuk Lymphoma; 2007 Dec; 48(12):2441-3. PubMed ID: 18067021 [No Abstract] [Full Text] [Related]
17. Five day intermittent vs seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia. Damasio EE; Resegotti L; Masoudi B; Bruni R; Cerri R; Isaza A; Clavio M; Risso M; Rossi E; Spriano M; Truini M Recenti Prog Med; 1998 Feb; 89(2):68-73. PubMed ID: 9558908 [TBL] [Abstract][Full Text] [Related]
18. Cladribine for the treatment of hairy cell leukemia and chronic lymphocytic leukemia. Rai KR Semin Oncol; 1998 Jun; 25(3 Suppl 7):19-22. PubMed ID: 9671325 [TBL] [Abstract][Full Text] [Related]
19. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Chihara D; Kantarjian H; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Poku R; Jain P; Thompson P; Brandt M; Luthra R; Burger J; Keating M; Ravandi F Br J Haematol; 2016 Sep; 174(5):760-6. PubMed ID: 27301277 [TBL] [Abstract][Full Text] [Related]
20. Histological examination of the lacrimal gland after experimental administration of Cladribine. Kwietniewska M; Czerny K Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):526-30. PubMed ID: 12898890 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]